MA35345B1 - Proteines de liaisons a un antigene ayant une liaison accrue a fcrn - Google Patents
Proteines de liaisons a un antigene ayant une liaison accrue a fcrnInfo
- Publication number
- MA35345B1 MA35345B1 MA36748A MA36748A MA35345B1 MA 35345 B1 MA35345 B1 MA 35345B1 MA 36748 A MA36748 A MA 36748A MA 36748 A MA36748 A MA 36748A MA 35345 B1 MA35345 B1 MA 35345B1
- Authority
- MA
- Morocco
- Prior art keywords
- binding
- proteins
- fcrn
- antigen
- increased
- Prior art date
Links
- 101150050927 Fcgrt gene Proteins 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 229960002964 adalimumab Drugs 0.000 abstract 2
- 102000025171 antigen binding proteins Human genes 0.000 abstract 2
- 108091000831 antigen binding proteins Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1112429.4A GB201112429D0 (en) | 2011-07-19 | 2011-07-19 | Antigen-binding proteins with increased FcRn binding |
| PCT/EP2012/064129 WO2013011076A2 (en) | 2011-07-19 | 2012-07-19 | Antigen-binding proteins with increased fcrn binding |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35345B1 true MA35345B1 (fr) | 2014-08-01 |
Family
ID=44586854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36748A MA35345B1 (fr) | 2011-07-19 | 2014-02-12 | Proteines de liaisons a un antigene ayant une liaison accrue a fcrn |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20130243764A1 (enExample) |
| EP (2) | EP3009450A1 (enExample) |
| JP (1) | JP2014524748A (enExample) |
| KR (1) | KR20140054085A (enExample) |
| CN (1) | CN103748110A (enExample) |
| AU (1) | AU2012285786B2 (enExample) |
| BR (1) | BR112014000341A2 (enExample) |
| CA (1) | CA2841105A1 (enExample) |
| CL (1) | CL2014000134A1 (enExample) |
| CO (1) | CO6862106A2 (enExample) |
| CR (1) | CR20140029A (enExample) |
| DO (1) | DOP2014000007A (enExample) |
| EA (1) | EA201391789A1 (enExample) |
| ES (1) | ES2600854T3 (enExample) |
| GB (1) | GB201112429D0 (enExample) |
| MA (1) | MA35345B1 (enExample) |
| MX (1) | MX2014000739A (enExample) |
| PE (1) | PE20141660A1 (enExample) |
| PH (1) | PH12014500167A1 (enExample) |
| SG (1) | SG10201601154QA (enExample) |
| WO (1) | WO2013011076A2 (enExample) |
| ZA (1) | ZA201400062B (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2385745C (en) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| UY33679A (es) | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
| US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| KR101730694B1 (ko) * | 2012-03-07 | 2017-04-27 | 카딜라 핼쓰캐어 리미티드 | TNF-α 항체의 약제학적 제형 |
| US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| WO2013158275A1 (en) * | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Cell culture methods to reduce acidic species |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| US20150150982A1 (en) * | 2012-06-12 | 2015-06-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulation for a therapeutic antibody |
| EP2890782A1 (en) | 2012-09-02 | 2015-07-08 | AbbVie Inc. | Methods to control protein heterogeneity |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| PE20191815A1 (es) | 2012-09-07 | 2019-12-27 | Coherus Biosciences Inc | Formulaciones acuosas estables de adalimumab |
| FR2999431B1 (fr) * | 2012-12-17 | 2016-03-18 | Lfb Biotechnologies | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
| WO2014096672A1 (fr) * | 2012-12-17 | 2014-06-26 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
| CN105051064A (zh) * | 2013-01-24 | 2015-11-11 | 葛兰素史克知识产权开发有限公司 | 抗TNF-α抗原结合蛋白 |
| HK1207960A1 (en) | 2013-03-12 | 2016-02-19 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| WO2014158231A1 (en) * | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Low acidic species compositions and methods for producing and using the same |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
| EP3021833B2 (en) * | 2013-07-19 | 2022-03-30 | Hexal Aktiengesellschaft | Methods and formulations which allow the modulation of immune responses related to the administration of a biopharmaceutical drug |
| US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| CN106170298B (zh) * | 2013-10-16 | 2024-01-09 | 前瞻疗法公司 | 用于提高抗体稳定性的缓冲液制剂 |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| EP3050557A1 (en) * | 2014-05-23 | 2016-08-03 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP2946766B1 (en) | 2014-05-23 | 2016-03-02 | Ares Trading S.A. | Liquid pharmaceutical composition |
| ES2607489T3 (es) | 2014-05-23 | 2017-03-31 | Ares Trading S.A. | Composición farmacéutica líquida |
| US10059763B2 (en) | 2014-09-03 | 2018-08-28 | Boehringer Ingelheim International Gmbh | Compound targeting IL-23A and TNF-alpha and uses thereof |
| HUP1400510A1 (hu) * | 2014-10-28 | 2016-05-30 | Richter Gedeon Nyrt | Gyógyászati TNFalfa ellenes antitest készítmény |
| US10696735B2 (en) | 2015-01-21 | 2020-06-30 | Outlook Therapeutics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
| AR103544A1 (es) * | 2015-01-28 | 2017-05-17 | Mabxience S A | FORMULACIONES FARMACÉUTICAS PARA ANTICUERPOS ANTI-TNF-a |
| WO2016189491A1 (en) * | 2015-05-28 | 2016-12-01 | Glaxosmithkline Intellectual Property Development Limited | Novel formulation |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
| EP3395835B1 (en) | 2015-12-25 | 2021-02-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody having enhanced activity, and method for modifying same |
| MX2018009341A (es) | 2016-02-03 | 2019-05-15 | Oncobiologics Inc | Formulaciones tamponadas para una mayor estabilidad de anticuerpos. |
| TN2018000301A1 (en) | 2016-03-14 | 2020-01-16 | Univ Oslo | Engineered immunoglobulins with altered fcrn binding |
| US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
| TWI820000B (zh) | 2016-04-28 | 2023-11-01 | 日商中外製藥股份有限公司 | 含抗體製劑 |
| KR20250036943A (ko) | 2016-08-02 | 2025-03-14 | 비스테라, 인크. | 조작된 폴리펩티드 및 그의 용도 |
| TW202300515A (zh) * | 2016-10-20 | 2023-01-01 | 法商賽諾菲公司 | 抗ｃｈｉｋｖ抗體及其用途 |
| CN110167531B (zh) * | 2017-01-11 | 2025-06-03 | 赛特瑞恩股份有限公司 | 稳定的液体调配物 |
| WO2018129713A1 (zh) * | 2017-01-13 | 2018-07-19 | 杭州翰思生物医药有限公司 | 提高IgG类抗体对FcRn的结合亲和力并延长其血清半衰期的方法 |
| US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
| EP3372242A1 (en) * | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP3372241A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| AU2018314257B2 (en) * | 2017-08-11 | 2025-03-27 | Research Development Foundation | Engineered antibody Fc variants for enhanced serum half life |
| KR20190024572A (ko) * | 2017-08-30 | 2019-03-08 | (주)셀트리온 | TNFα 관련 질환을 치료하기 위한 피하 투여 요법 |
| AR113816A1 (es) | 2017-11-01 | 2020-06-17 | Chugai Pharmaceutical Co Ltd | Variantes e isoformas de anticuerpos con actividad biológica reducida |
| IL318916A (en) * | 2018-01-26 | 2025-04-01 | Genzyme Corp | FC variants with improved binding to FCRN and extended half-life |
| KR20210137499A (ko) * | 2019-03-05 | 2021-11-17 | 더 스테이트 오브 이스라엘, 미니스트리 오브 애그리컬처 & 루럴 디벨로프먼트, 애그리컬처럴 리서치 오거니제이션, (에이.알.오.), 볼카니 센터 | 게놈-편집 조류 |
| CN115770291A (zh) * | 2021-09-08 | 2023-03-10 | 珠海市丽珠单抗生物技术有限公司 | 新型冠状病毒SARS-CoV-2疫苗加强免疫及其应用 |
| CN115770292A (zh) * | 2021-09-08 | 2023-03-10 | 珠海市丽珠单抗生物技术有限公司 | 新型冠状病毒SARS-CoV-2的协同免疫及其用途 |
| EP4434517A4 (en) * | 2021-11-30 | 2025-06-25 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-sost antibody pharmaceutical composition and use thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| DK0929578T3 (da) * | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US7658921B2 (en) * | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| DK1355919T3 (da) * | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| CA2502904C (en) | 2002-10-15 | 2013-05-28 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| US8034906B2 (en) * | 2006-10-27 | 2011-10-11 | Abbott Biotechnology Ltd. | Crystalline anti-hTNFalpha antibodies |
| CN101848936B (zh) | 2007-08-20 | 2017-05-03 | 葛兰素集团有限公司 | 生产方法 |
| UY31504A1 (es) * | 2007-11-30 | 2009-07-17 | Construcciones de union de antigenos | |
| KR20150080038A (ko) * | 2007-11-30 | 2015-07-08 | 애브비 바이오테크놀로지 리미티드 | 단백질 제형 및 이의 제조방법 |
| WO2009073805A2 (en) * | 2007-12-04 | 2009-06-11 | Verdezyne, Inc. | Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences |
| KR101616758B1 (ko) * | 2007-12-26 | 2016-04-29 | 젠코어 인코포레이티드 | ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체 |
| US8399627B2 (en) * | 2007-12-31 | 2013-03-19 | Bayer Pharma AG | Antibodies to TNFα |
| FR2934599B1 (fr) | 2008-07-29 | 2012-12-21 | Arkema France | Fabrication de polyethylene a partir de matieres renouvelables, polyethylene obtenu et utilisations |
| CA2738243C (en) * | 2008-10-29 | 2020-09-29 | Wyeth Llc | Formulations of single domain antigen binding molecules |
| JP2012518398A (ja) * | 2009-02-24 | 2012-08-16 | グラクソ グループ リミテッド | 抗原結合性構築物 |
| KR101579771B1 (ko) * | 2009-03-05 | 2015-12-28 | 애브비 인코포레이티드 | Ｉｌ-17 결합 단백질 |
| CA2760185A1 (en) * | 2009-05-04 | 2010-11-11 | Abbott Biotechnology Ltd. | Stable high protein concentration formulations of human anti-tnf-alpha antibodies |
| WO2010136492A2 (en) * | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Antigen-binding proteins |
| WO2011074965A1 (en) * | 2009-12-17 | 2011-06-23 | Stichting Sanquin Bloedvoorziening | Methods and means for counteracting an activity of an fc domain |
| US8821865B2 (en) | 2010-11-11 | 2014-09-02 | Abbvie Biotechnology Ltd. | High concentration anti-TNFα antibody liquid formulations |
-
2011
- 2011-07-19 GB GBGB1112429.4A patent/GB201112429D0/en not_active Ceased
-
2012
- 2012-07-19 CN CN201280034887.5A patent/CN103748110A/zh active Pending
- 2012-07-19 WO PCT/EP2012/064129 patent/WO2013011076A2/en not_active Ceased
- 2012-07-19 US US13/988,400 patent/US20130243764A1/en not_active Abandoned
- 2012-07-19 ES ES12738101.0T patent/ES2600854T3/es active Active
- 2012-07-19 AU AU2012285786A patent/AU2012285786B2/en not_active Ceased
- 2012-07-19 EP EP15197750.1A patent/EP3009450A1/en not_active Withdrawn
- 2012-07-19 KR KR1020147004161A patent/KR20140054085A/ko not_active Withdrawn
- 2012-07-19 EP EP12738101.0A patent/EP2734548B1/en active Active
- 2012-07-19 BR BR112014000341A patent/BR112014000341A2/pt not_active IP Right Cessation
- 2012-07-19 PE PE2014000086A patent/PE20141660A1/es not_active Application Discontinuation
- 2012-07-19 SG SG10201601154QA patent/SG10201601154QA/en unknown
- 2012-07-19 CA CA2841105A patent/CA2841105A1/en not_active Abandoned
- 2012-07-19 PH PH1/2014/500167A patent/PH12014500167A1/en unknown
- 2012-07-19 EA EA201391789A patent/EA201391789A1/ru unknown
- 2012-07-19 MX MX2014000739A patent/MX2014000739A/es unknown
- 2012-07-19 JP JP2014520658A patent/JP2014524748A/ja active Pending
-
2014
- 2014-01-06 ZA ZA2014/00062A patent/ZA201400062B/en unknown
- 2014-01-17 DO DO2014000007A patent/DOP2014000007A/es unknown
- 2014-01-17 CL CL2014000134A patent/CL2014000134A1/es unknown
- 2014-01-20 CR CR20140029A patent/CR20140029A/es unknown
- 2014-01-21 CO CO14011137A patent/CO6862106A2/es not_active Application Discontinuation
- 2014-02-12 MA MA36748A patent/MA35345B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3009450A1 (en) | 2016-04-20 |
| AU2012285786A1 (en) | 2014-02-06 |
| NZ618897A (en) | 2016-02-26 |
| CO6862106A2 (es) | 2014-02-10 |
| PE20141660A1 (es) | 2014-11-21 |
| SG10201601154QA (en) | 2016-03-30 |
| CN103748110A (zh) | 2014-04-23 |
| MX2014000739A (es) | 2014-02-19 |
| AU2012285786B2 (en) | 2016-05-12 |
| ZA201400062B (en) | 2017-08-30 |
| WO2013011076A3 (en) | 2013-04-04 |
| EA201391789A1 (ru) | 2014-06-30 |
| EP2734548B1 (en) | 2016-08-17 |
| ES2600854T3 (es) | 2017-02-13 |
| DOP2014000007A (es) | 2014-04-30 |
| US20130243764A1 (en) | 2013-09-19 |
| CA2841105A1 (en) | 2013-01-24 |
| BR112014000341A2 (pt) | 2017-02-14 |
| KR20140054085A (ko) | 2014-05-08 |
| PH12014500167A1 (en) | 2019-03-22 |
| WO2013011076A2 (en) | 2013-01-24 |
| CR20140029A (es) | 2014-03-05 |
| GB201112429D0 (en) | 2011-08-31 |
| JP2014524748A (ja) | 2014-09-25 |
| CL2014000134A1 (es) | 2014-07-25 |
| EP2734548A2 (en) | 2014-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35345B1 (fr) | Proteines de liaisons a un antigene ayant une liaison accrue a fcrn | |
| MA29374B1 (fr) | Anticorps anti-ccr5 et leurs utilisations | |
| MA34927B1 (fr) | Anticorps anti-cea | |
| MA35428B1 (fr) | Proteines et peptides podifies | |
| MA35740B1 (fr) | Compositions et procédés pour des anticorps ciblant le facteur p | |
| MA37761A1 (fr) | Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations | |
| MA29279B1 (fr) | Molecules de liaison d'antigenes se liant au recepteur egfr, vecteurs codant pour ces molecules et leurs applications | |
| MA35174B1 (fr) | Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines | |
| TNSN07398A1 (fr) | Anticorps contre la p-cadherine | |
| MA40801A1 (fr) | Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123 | |
| MA32577B1 (fr) | Anticorps neutralisants le virus de l'influenza a et leurs utilisations | |
| CA2868907C (en) | Anti-hla-b*27 antibodies and uses thereof | |
| MA29226B1 (fr) | Anticorps diriges contre le recepteur alpha 1 de il-13 et leurs utilisations | |
| MA33387B1 (fr) | Polypeptides et procede de traitement | |
| MXPA06012601A (es) | Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos. | |
| MA34527B1 (fr) | Anticorps contre la metalloproteinase de matrice 9 | |
| MA38161A1 (fr) | Anticorps anti-bmp-6 | |
| MA49355A (fr) | Formats de récepteurs de liaison d'antigène améliorés | |
| UA108066C2 (uk) | Білки, що зв'язуються з cgrp-рецепторами людини | |
| WO2008105886A3 (en) | HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | |
| MX2010009190A (es) | Anticuerpos anti-c5ar humanizados. | |
| EA200870274A1 (ru) | ПЕПТИДЫ, БЛОКИРУЮЩИЕ СВЯЗЫВАНИЕ IgG C FcRn | |
| WO2014114651A9 (en) | Tnf-alpha antigen-binding proteins | |
| MA28982B1 (fr) | Anticorps antagonistes de il-17 | |
| MA31838B1 (fr) | Anticorps se liant à l'il-4 et/ou à l'il-3 et leurs utilisations |